Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 1.00 |
| ▸ | NFATC1 | O95644 | 6/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.63 |
| ▸ | PIM1 | P11309 | 1/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.58 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25421202 | 1.00 | DYRK1A (1.00) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 | |
| SCHEMBL26696137 | 0.89 | DYRK1A (0.80) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 | |
| SCHEMBL17179566 | 0.84 | DYRK1A (1.00) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 | |
| SCHEMBL16596104 | 0.82 | DYRK1A (0.70) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 | |
| SCHEMBL29431212 | 0.81 | IMPDH2 (1.00) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 | |
| SCHEMBL238277 | 0.81 | IMPDH2 (1.00) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 | |
| SCHEMBL31472564 | 0.81 | DYRK1A (1.00) | DYRK1ANFATC1GSK3BIMPDH2HASPIN | |
| SCHEMBL25910370 | 0.80 | DYRK1A (0.66) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 | |
| SCHEMBL13051138 | 0.77 | DYRK1A (0.65) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 | |
| SCHEMBL18418490 | 0.77 | TDO2 (0.72) | DYRK1ANFATC1GSK3BIMPDH2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | DYRK1A 2/4885NFATC1 2381/4885GSK3B 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.